Literature DB >> 31712062

Anti-androgen hormonal therapy for cancer and other diseases.

Sebastian Student1, Tomasz Hejmo2, Aleksandra Poterała-Hejmo3, Aleksandra Leśniak4, Rafał Bułdak2.   

Abstract

The development of targeted therapies has been a consistent goal for hormone-related diseases treatment. As a result of increased knowledge of the role of androgens in different diseases, anti-androgen treatment is becoming increasingly important in targeted therapy. Androgens play an important role in different disorders, therefore, androgen receptor signalling is a crucial factor in pathological conditions. The androgen receptor is a transcription factor activated by the testosterone metabolite 5α-dihydrotestosterone and regulates the expression of genes related to sexual differentiation, growth and survival of prostate cells, and to a certain extent, cancer progression. Herein, we review anti-androgen therapies in cancer and other selected diseases and provide examples where anti-androgen drugs can be used as both main and supportive treatments in the multimodal therapeutic scheme. Even in diseases with low serum levels of testosterone or DHT, anti-androgen therapy plays an important role in new treatments. Therefore, the use of anti-androgens is an appealing strategy in which to overcome resistance to primary treatment by assuring better therapy results. In this review, we take into account both older generation hormonal drugs and the new drug classes. Additionally, we review recent studies that suggest new anti-androgen agents have not entirely replaced some of the old standards.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Androgens; Anti-androgen drugs; Breast cancer; Cancer therapy; Hormonal therapy; Prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31712062     DOI: 10.1016/j.ejphar.2019.172783

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.

Authors:  Liuxun Li; Jiangli Xu
Journal:  Clin Transl Oncol       Date:  2022-10-06       Impact factor: 3.340

Review 2.  Nanoimmunoengineering strategies in cancer diagnosis and therapy.

Authors:  Robabehbeygom Ghafelehbashi; Melina Farshbafnadi; Niloofar Shokraneh Aghdam; Shahin Amiri; Mitra Salehi; Sepideh Razi
Journal:  Clin Transl Oncol       Date:  2022-09-08       Impact factor: 3.340

Review 3.  Crosstalk between estrogen, dendritic cells, and SARS-CoV-2 infection.

Authors:  Daniela Mateus; Ana Isabel Sebastião; Mylène A Carrascal; Anália do Carmo; Ana Miguel Matos; Maria Teresa Cruz
Journal:  Rev Med Virol       Date:  2021-09-17       Impact factor: 11.043

4.  Androgen Receptor Protein Degradation in the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-02-09       Impact factor: 4.345

Review 5.  Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?

Authors:  Maria Luisa Brandi
Journal:  Rev Endocr Metab Disord       Date:  2021-11-10       Impact factor: 9.306

Review 6.  Endocrine Disruptors and Prostate Cancer.

Authors:  Margherita Corti; Stefano Lorenzetti; Alessandro Ubaldi; Romano Zilli; Daniele Marcoccia
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

7.  Consumption of flavonoids and risk of hormone-related cancers: a systematic review and meta-analysis of observational studies.

Authors:  Fubin Liu; Yu Peng; Yating Qiao; Yubei Huang; Fengju Song; Ming Zhang; Fangfang Song
Journal:  Nutr J       Date:  2022-05-11       Impact factor: 4.344

Review 8.  Lysine Acetyltransferases and Their Role in AR Signaling and Prostate Cancer.

Authors:  Bharti Jaiswal; Akanksha Agarwal; Ashish Gupta
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-17       Impact factor: 6.055

9.  Chromosome X aneusomy and androgen receptor gene copy number aberrations in apocrine carcinoma of the breast.

Authors:  Anna Cremonini; Luca Saragoni; Luca Morandi; Angelo G Corradini; Caterina Ravaioli; Enrico Di Oto; Francesco Limarzi; Alejandro M Sanchez; Maria C Cucchi; Riccardo Masetti; Cecily Quinn; Maria P Foschini
Journal:  Virchows Arch       Date:  2021-02-03       Impact factor: 4.064

Review 10.  Roles of steroid receptors in the lung and COVID-19.

Authors:  Damien A Leach; Greg N Brooke; Charlotte L Bevan
Journal:  Essays Biochem       Date:  2021-12-17       Impact factor: 8.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.